Thromboembolic disorders:

Indications for: YOSPRALA

Patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. For separate components: see full labeling.

Limitations of Use:

Not for use as initial dose of aspirin therapy during onset of acute coronary syndrome, acute MI, or before PCI. Not shown to reduce risk of GI bleeding due to aspirin. Not interchangeable with individual aspirin and omeprazole.

Adult Dosage:

Swallow whole. Take 1 tab daily at least 1hr before a meal. Use lowest effective dose for shortest duration. Usually aspirin 81mg is acceptable; can consider the need for 325mg and refer to current guidelines.

Children Dosage:

Not established.

YOSPRALA Contraindications:

NSAID allergy and syndrome of asthma, rhinitis, nasal polyps. Viral infections in pediatric patients. Concomitant rilpivirine-containing drugs (due to omeprazole component).

YOSPRALA Warnings/Precautions:

Coagulation abnormalities; monitor for increased bleeding. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). Discontinue if significant bleeding from any source, acute tubulointerstitial nephritis, severe cutaneous adverse reactions, or cutaneous/systemic lupus erythematosus develops. Gastric malignancy. Increased risk of fundic gland polyps with long-term use (esp. >1yr) or osteoporosis-related fractures (hip, wrist or spine) with long-term (>1yr) and multiple daily dose PPI therapy. Long-term therapy (>3yrs) may lead to malabsorption/deficiency of Vit. B12. Monitor for hypomagnesemia during prolonged therapy. Consider monitoring magnesium, calcium levels in those with preexisting risk of hypocalcemia (eg, hypoparathyroidism). Avoid abrupt cessation. Pre-existing renal disease. Hepatic impairment or severe renal impairment (GFR <10mL/min): not recommended. Asians with unknown CYP2C19 genotype or known to be poor metabolizers: not recommended. Elderly. Labor & delivery. Pregnancy (≥30 weeks gestation: avoid). Nursing mothers: not recommended.

YOSPRALA Classification:

Antiplatelet + proton pump inhibitor.

YOSPRALA Interactions:

See Contraindications. Concomitant St. John's wort, rifampin, atazanavir, nelfinavir, voriconazole: not recommended. Concomitant heparin, warfarin: monitor and adjust dose as needed. Avoid concomitant clopidogrel; consider alternative antiplatelet therapy. Potentiates saquinavir, hypoglycemics, acetazolamide, valproic acid, citalopram (limit to max 20mg daily), cilostazol (reduce to 50mg twice daily). May potentiate phenytoin, diazepam, tacrolimus, digoxin, methotrexate (consider temporary withdrawal if on high-doses); monitor and adjust dose as needed. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics; monitor. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction. Caution with drugs that may cause hypomagnesemia (eg, digoxin, diuretics); monitor. May alter absorption of pH-dependent drugs (eg, iron salts, erlotinib, dasatinib, nilotinib, ketoconazole, itraconazole, mycophenolate mofetil). Monitor drugs metabolized by CYP450 (eg, cyclosporine, disulfiram). May interfere with lab tests; discontinue ≥14 days prior to CgA level assessment and secretin stimulation test. May cause false (+) THC urine test; use alternative confirmatory method. For the 325mg/40mg tab strength: avoid concomitant ticagrelor.

Adverse Reactions:

Gastritis, nausea, diarrhea, gastric polyps, non-cardiac chest pain; ulcers (monitor), abnormal lab tests (eg, increased liver enzymes, BUN, creatinine, hyperkalemia, proteinuria, prolonged bleeding time); possible C. diff-associated diarrhea, reversible infertility; rare: hypomagnesemia and mineral metabolism.

Generic Drug Availability:


How Supplied:

Tabs—30, 90